Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
120Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-26.97M | $-2.98 |
| 2024 | $0.00 | $-16.29M | $-2.02 |
| 2023 | $0.00 | $-2.17M | $-0.82 |
| 2022 | $0.00 | $-5.80M | $-11.20 |
| 2021 | $0.00 | $-24.10M | $-18.51 |
Social Signal Score
Earnings
Fri, Nov 6(in 3 months)
Consensus estimate $-0.53 per share
Typical surprise -11.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.64 vs $-0.80beat
- Mon, May 18$-0.86 vs $-0.90beat
- Fri, Mar 13$-0.88 vs $-0.79miss
- Fri, Nov 7$-0.84 vs $-0.68miss
- Fri, Aug 8$-0.70 vs $-0.61miss
- Mon, May 12$-0.56 vs $-0.60beat
Estimates and results for CRVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CRVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·5d ago·Positive
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP) for development in DLB New analyses presented at the Alzheimer's Association International Conference (AAIC) 2026 reinforce neflamapimod's treatment effect in pur
View source ↗